Objective:To observe the clinical efficacy of “Qishen Erlian Decoction” combined with Entecavir on patients with chronic hepatitis B. Methods62 patients with chronic hepatitis B were randomly divided into control group (30 cases) and treatment group (32 cases), in which the control group received Entecavir tablets while the treatment group received “Qishen Erlian Decoction” on the basis of Entecavir tablets. Two groups of patients with a course of 1 year and were followed up for 6 Months. We observed the virological responses, e antigen conversion rates, liver function(ALT, AST, TBIL) and IL4, IFN-γlevels.  Results:①The EVR of the two groups was 68.75% and 33.33%, ETVR was 78.13% and 50%, SVR was 71.88% and 36.67%, the difference was statistically significant (P<0.05); ②Compared between the two groups after the treatment and 6 months follow-up, difference was statistically significant on the e antigen conversion rate (P<0.05); ③Comparison with pre-treatment, difference were statistically significant in AST, ALT, TBIL levels of both groups (P<0.05), between the two groups after treatment, AST, ALT, TBIL levels had no significant difference (P>0.05); ④Comparison with pre-treatment, difference were statistically significant in IL-4, IFN-γ levels of both groups (P<0.05), between the two groups after the treatment, IL-4, IFN-γ levels were significantly (P<0.05 ); between the two groups at follow-up to 6 months, IL-4, IFN-γ levels were significantly (P<0.05).  Conclusion:The clinical effect of “Qishen Erlian Decoction” combined with Entecaviris on patients with chronic hepatitis B was significant, not only can significantly inhibit the replication of HBV-DNA, but also regulate IL4 and IFN-γ levels, thereby enhancing the body's ability to clear the virus, promoting e antigen conversion.